What makes someone with #ATTR #CM, NYHA class III, HF on diuretics, with NTproBNP 5k, do well over 4 years? Now NYHA I, same diuretics, no HF events, NTproBNP 3k. On tafamidis for 5 years, granted initially had worsening HF ~1 year then stabilized We are ok in predicting the extremes of prognosis in #ATTR #CM But we aren't anywhere near precise predictions for the majority in between. Therapies/clinical trials are complicating this further #Amyloidosis
Ahmad Masri’s Post
More Relevant Posts
-
Lenvatinib and pembrolizumab added to transarterial chemoembolisation (TACE) significantly improves PFS and shows an early trend toward improved OS versus TACE alone, according to a first interim analysis of the phase III LEAP-012 trial of intermediate-stage #HCC presented at #ESMO24. TACE is the standard-of-care therapy in this setting but is not curative, so there is an unmet need for improved locoregional treatments. Lorenza Rimassa believes the positive PFS data could influence future #ClinicalPractice, although longer follow-up is needed. 👇Read the full commentary on the #ESMODailyReporter https://ow.ly/loxX50TnAL5
-
-
In RRMM therapy Beyond I/O at IMS2024, expert notes there is still room and need for expansion of the MM armamentarium beyond the remarkable successes of T-cell redirecting therapies—non-immunologic ADCs, theranostics, new druggable pathways/targets—these offer opportunities. #IMS24
-
-
🔬 Innovative Breakthrough in Lupus Treatment 🔬 🚫 No Lymphodepletion Required: One of the most notable aspects of this therapy is that it can be administered without the use of lymphodepletion, reducing the burden on patients, physicians, and the healthcare system. This is especially important considering the significant comorbidities associated with SLE. Exciting news from Synthekine! Their unique combination therapy, SYNCAR-001 + STK-009, has been cleared by the FDA for a clinical trial in the US to tackle systemic lupus erythematosus (SLE) and lupus nephritis (LN) without the need for lymphodepletion. This marks a significant step forward in the treatment of these challenging autoimmune diseases. 🎯 The Power of Combination Therapy: The therapy combines an autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) product with an engineered pegylated IL-2 cytokine. This innovative approach aims to drive cell engraftment and controlled cell expansion, offering a potential game-changer for patients with nonrenal SLE and LN. 🌍 Global Potential: As this therapy moves into clinical trials, it holds the promise of addressing critical segments of the patient population who face barriers to treatment. With preclinical results showing control of cell expansion and activation, there's a remarkable potential benefit for those suffering from this devastating disease. 💡 Insight: This breakthrough demonstrates the power of innovative therapies in addressing key limitations of current treatments. As we continue to explore the potential of CAR-T cell therapies, it's exciting to see advancements like these that could significantly improve the lives of patients around the world. #LupusTreatment #Synthekine #CAR-TTherapy #InnovativeTherapies #AutoimmuneDiseases #ClinicalTrials #HealthcareInnovation
ICYMI: Synthekine anticipates enrollment of the first patient in the trial to take place in the second half of this year. #lupus #celltherapy #AutoimmuneDisease #CART Read more: https://lnkd.in/gGKjzF_c
-
-
Check out this insightful editorial by Tanaka et al on the value of #Clotpro and its unique #TPA-test. The Clot-Pro® TPA test helps in dose-response assessment to TXA, making it a useful tool in maintaining therapeutic TXA concentrations during postpartum hemorrhage. The findings are a testament to the clinical utility of this viscoelastic coagulation test. Read more: https://lnkd.in/gjRbyxey.
-
-
Today kicks off #SNMMI24. Iomab-B and Actimab-A are the only targeted #radiotherapies in development for r/r #AML addressing different parts of the patient journey. We look forward to our presentations highlighting the Phase 3 SIERRA trial and Phase 1b trial of Actimab-A results. $ATNM
-
-
Insightful recommendations form SMOB
The current limited availability of the GLP-1 receptor agonist (GLP-1 RA) product #Wegovy® (2.4 mg semaglutide) demands an urgent prioritization by means of which patientgroup should be treated first, second, etc. To support health care providers to make reasonable and (as much as possible) evidence-based clinical decisions, the #SMOB provides recommendations for the prioritization process. These were generated by an interdisciplinary task force consisting of Katharina Timper, Lucie Favre, Marco Bueter and Bernd Schultes. Please use and share as much as you can! Of course, comments, questions and any #feedback are more than welcome! #wegovy #taskforce #triage #obesity #treatment #bariatricsurgery
-
The NETTER-2 trial aimed to investigate the efficacy and safety of first-line treatment with [Lu]Lu-DOTA-TATE (Lu-Dotatate). #lutathera #LuPRRT #Ludotatate #radioligandtherapy #neuroendocrinetumor
-
-
Advanced Paramedic - IC | BLS , ACLS, PALS, NRP, PHTLS | SALT MC Triage ,EOP, MCI Triage
The modified Valsalva maneuver (mVm) has been shown to have a higher success rate in converting hemodynamically stable SVT to normal sinus rhythm (NSR) when compared to sVm (REVERT trial). MVm works by increasing venous return and vagal stimulation by laying patients supine and elevating their legs and has been shown to be a simple, safe and cost effective method. #emt #paramedic #ems
-
got fusion?… Catamaran does! We're excited to invite you to a compelling Lunch Workshop at the upcoming ISASS meeting on April 27th in Miami, Florida. Drs. Scott Kutz and Matthew Davies, MD, FAANS, renowned experts in the field, will lead a dynamic session titled "Mastering the SI Joint: A Comprehensive Approach to Diagnosis, Intervention and New Fusion Evidence." Workshop Focus: - Advanced SI Joint Diagnosis: Gain insights into Dr. Kutz and Dr. Davies' proven approach to diagnosing SI joint issues. - Catamaran® System Innovation: Explore the groundbreaking features of the Catamaran system designed to achieve true arthrodesis/fusion of the SI joint. - Real-World Evidence from Post-Market Study: Drs. Kutz and Davies will present and analyze promising early fusion rate data observed with Catamaran in our ongoing clinical study. We encourage you to register for the workshop and join us for this informative session. To register, scan the QR code below or click here https://hubs.ly/Q02q-FQY0 #ISASS24 #sijointfusion #sijointdysfunction #catamaran #sijoint #TenonMedical #spine #transfixsacroiliacjoint #jibkit #fusion #arthodesis
-